ProteoTech Receives Phase I SBIR Award from the National Institute on Aging to Study the Role of Proteoglycans in Brain During Development of Alzheimer's Disease

Kirkland, WA, June 5, 2003 – ProteoTech ("**Proteo**glycan **Tech**nologies) Inc. today announced that it has received a Phase I Small Business Research (SBIR) award from the National Institute on Aging. The $520,840 award to ProteoTech (with principal investigator, Alan D. Snow, Ph.D., President & CSO) will fund a 1-year study to analyze the regulation of proteoglycan genes and proteins that are believed to play a critical role in the pathogenesis of amyloid plaque development in Alzheimer's disease. In addition, the role of proteoglycans and related glycosaminoglycans as potential diagnostic markers in biological fluids for Alzheimer's disease is under intensive research efforts at ProteoTech.

This is ProteoTech's 8th SBIR award during the last 4 years from the National Institute of Health, with over $6 million in funding acquired to develop new therapeutics and diagnostics for Alzheimer's and other amyloid diseases. ProteoTech is rated #1 in the State of Washington in receiving SBIR awards from the National Institute of Health. At the recent 9th International Conference on Alzheimer's Disease (Philadelphia, PA, July 2004) ProteoTech scientists presented evidence that its small molecule lead therapeutic for Alzheimer's disease demonstrates a marked clearance of brain amyloid plaques and improved memory in a relevant transgenic mouse model of Alzheimer's disease. ProteoTech is in late pre-clinical development of a disease-modifying small molecule therapeutic for Alzheimer's disease treatment. In addition, ProteoTech is developing a small peptide therapeutic for the treatment of Alzheimer's disease.

In related news, on July 27, 2004, ProteoTech was issued U.S. Patent No. 6,767,898 entitled "Methods for Using Specific Saccharides for Treating Alzheimer's Disease and Other Amyloidoses". The patent invented by Gerardo M. Castillo, Ph.D. and Alan D. Snow, Ph.D. pertains to the use of specific sulfated saccharides (small carbohydrate molecules) for the treatment of Alzheimer's disease and other amyloid disorders. This is ProteoTech's 10th patent to be issued pertaining to therapeutic, diagnostic and platform technologies for Alzheimer's disease and other amyloidoses.

ProteoTech is a private, product oriented Company that utilizes Proteoglycan Technologies to discover and develop drugs for treating human amyloid diseases. Proteoglycans are synthesized by virtually all cells of the body and play significant roles in the pathogenesis of insoluble toxic amyloid deposits thought to play important roles in a number of human disorders including Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloidosis. ProteoTech has research and development programs in all of these disease areas. ProteoTech is currently completing a Series B private financing and interested investors should contact Alan D. Snow, Ph.D., President & CSO at snow@proteotech.com.